BTG plc: Completion of the Acquisition of Protherics PLC

08-Dec-2008 - BTG plc announced that all the conditions to its recommended offer for Protherics PLC have been satisfied and the Acquisition has therefore been completed. Accordingly, 104,044,710 new BTG ordinary shares of 10 pence each issued in connection with the Acquisition were admitted to the Official ...

BTG licenses novel anticancer compound to Onyx Pharmaceuticals

BTG to receive $13m upfront plus potential milestones of up to $307m and sales royalties

11-Nov-2008 - BTG plc announced it has granted worldwide rights to Onyx Pharmaceuticals, Inc. to develop and commercialise BTG’s novel anticancer compound, BGC 945. Under the terms of the agreement, BTG will receive an upfront payment of $13m and has the potential to receive development milestone payments of ...

BTG plc: Tolerx initiates dosing of otelixizumab in a phase III clinical trial in type 1 diabetes

Tolerx to pay milestone of $7.5 million to BTG

08-Aug-2008 - BTG plc notes the announcement by Tolerx, Inc. that it has initiated a pivotal phase III clinical trial of otelixizumab (TRX4) in patients with new onset type 1 diabetes. Initiation of the DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes) triggers a milestone ...

BTG: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer

25-Jul-2008 - BTG plc notes the publication of a new study in the Journal of Clinical Oncology showing that abiraterone caused significant tumour shrinkage and reduction in prostate specific antigen (PSA) levels in 70-80% of men with advanced, chemotherapy-resistant prostate cancer. BTG acquired abiraterone ...

BTG plc: Acquisition of Protez Pharmaceuticals by Novartis

BTG to receive approximately $5 million in respect of its shareholding in Protez upon close of transaction with further potential payments

09-Jun-2008 - BTG plc noted an announcement by Novartis that is to acquire Protez Pharmaceuticals, a company focused on the discovery and development of novel antibiotics that was founded in 2003 by BTG alongside Protez management members Chris Cashman, Dr Klauss Esser and Dr Luigi Xerri. Novartis is ...

BTG Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnoea Patients

Novel Combination Therapy Shown to be Well-Tolerated and to Reduce the Apnoea-Hypopnoea Index in OSA Patients

14-Apr-2008 - BTG reports additional details from its positive clinical proof of concept study of BGC20-0166 in subjects with mild to severe obstructive sleep apnoea. BGC20-0166 is a novel combination of two marketed serotonin modulating drugs being developed for the treatment of obstructive sleep apnoea ...

BTG Initiates Clinical Study of Novel Multiple Sclerosis Treatment

10-Mar-2008 - BTG plc announced that dosing has commenced in a Phase I clinical study of BGC20-0134, a potential treatment for multiple sclerosis. The randomised, double-blind, placebo-controlled study will assess the pharmacodynamic, pharmacokinetic and safety profiles of single and multiple oral doses of ...

BTG plc commences first clinical study of novel migraine treatment

01-Feb-2008 - BTG plc announced that BGC20-1531, a potential treatment for migraine headaches, has commenced clinical development. Dosing has begun in a randomised, double-blind, placebo controlled phase I study, which will assess the safety, tolerability and pharmacokinetic profile of single rising doses of ...

BTG plc: Orphan Drug status granted for anticancer drug plevitrexed

11-Jun-2007 - BTG Plc announced that its cancer drug plevitrexed (BGC 9331) has been granted US orphan drug designation for ovarian and gastric cancer indications. Plevitrexed is a potent, selective thymidylate synthase inhibitor targeting gastric, pancreatic and ovarian cancers. In January 2007, the results ...

BTG signs agreement with Novacea and KuDOS for AQ4N

23-Apr-2007 - BTG plc announced that it has signed an agreement with Novacea, Inc. and KuDOS Pharmaceuticals Ltd (KuDOS), a wholly owned subsidiary of AstraZeneca UK Ltd, regarding the anti-cancer pro-drug AQ4N. Under the terms of the agreement, BTG will receive a signature fee and Novacea gains additional ...